{"product_id":"a-cato-recent-advances-in-glucocorticoid-receptor-action-9783540432296","title":"Recent Advances in Glucocorticoid Receptor Action","description":"Since 1948, hydrocortisone (cortisol), the principal glucocorticoid (GC) of the human adrenal cortex has been successfully used at phar­ macological concentrations for the suppression of clinical manifesta­ tions of rheumatoid arthritis. Numerous compounds with GC activity have also been developed and used. Fifty years after their initial clinical use, GCs are still the most im­ portant and frequently prescribed class of anti-inflammatory drugs for various inflammatory disorders. They are administered either orally, parenterally (intravenous, intramuscular, intrathecal), or topically (cu­ taneous, intranasal, pulmonic, rectal). Despite the many beneficial ef­ fects of GCs, they also have their limitations and disadvantages that occur with varying prevalence on different organs and after different durations of therapy. These side-effects can range in severity from cos­ metic (e.g. telangiectasias, hypertrichosis) to seriously disabling (e.g. induction of glaucoma, diabetes, osteoporosis) or even life-threatening disorders (e.g. gastric haemorrhage). These adverse effects of GCs se­ riously handicap their successful use as anti-inflammatory agents. There is therefore a strong need for the development of substances with the anti-inflammatory potency of classical GCs but with reduced side-effects.","brand":"Springer","offers":[{"title":"Used - good","offer_id":53184623247702,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0925\/5829\/5382\/files\/product_image_9783540432296_1.jpg?v=1778481589","url":"https:\/\/www.momoxbooks.com\/products\/a-cato-recent-advances-in-glucocorticoid-receptor-action-9783540432296","provider":"momoxbooks","version":"1.0","type":"link"}